Skip to content
2000
Volume 25, Issue 2
  • ISSN: 1871-5265
  • E-ISSN: 2212-3989
Preview this article:

There is no abstract available.

Loading

Article metrics loading...

/content/journals/iddt/10.2174/0118715265341206240722050403
2024-07-22
2025-01-01
Loading full text...

Full text loading...

/deliver/fulltext/iddt/25/2/IDDT-25-2-03.html?itemId=/content/journals/iddt/10.2174/0118715265341206240722050403&mimeType=html&fmt=ahah

References

  1. RavelliA. MinoiaF. DavìS. 2016 classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: A european league against rheumatism/american college of rheumatology/paediatric rheumatology international trials organisation collaborative initiative.Arthritis Rheumatol.201668356657610.1002/art.39332 26314788
    [Google Scholar]
  2. GromA.A. PassoM. Macrophage activation syndrome in systemic juvenile rheumatoid arthritis.J. Pediatr.1996129563063210.1016/S0022‑3476(96)70140‑3 8917224
    [Google Scholar]
  3. SchulertG.S. GromA.A. Macrophage activation syndrome and cytokine-directed therapies.Best Pract. Res. Clin. Rheumatol.201428227729210.1016/j.berh.2014.03.002 24974063
    [Google Scholar]
  4. SheuK.M. HoffmannA. Functional hallmarks of healthy macrophage responses: Their regulatory basis and disease relevance.Annu. Rev. Immunol.202240129532110.1146/annurev‑immunol‑101320‑031555 35471841
    [Google Scholar]
  5. SreejitG. FleetwoodA.J. MurphyA.J. NagareddyP.R. Origins and diversity of macrophages in health and disease.Clin. Transl. Immunology2020912e122210.1002/cti2.1222 33363732
    [Google Scholar]
  6. Gerfaud-ValentinM. SèveP. HotA. BroussolleC. JamillouxY. Pathophysiology, subtypes, and treatments of adult-onset Still’s disease: An update.Rev. Med. Interne201536531932710.1016/j.revmed.2014.10.365
    [Google Scholar]
  7. MosserD.M. EdwardsJ.P. Exploring the full spectrum of macrophage activation.Nat. Rev. Immunol.200881295896910.1038/nri2448 19029990
    [Google Scholar]
  8. LerkvaleekulB. VilaiyukS. Macrophage activation syndrome: Early diagnosis is key.Open Access Rheumatol.20181011712810.2147/OARRR.S151013 30214327
    [Google Scholar]
  9. StabileA. BertoniB. AnsuiniV. La TorracaI. SallìA. RiganteD. The clinical spectrum and treatment options of macrophage activation syndrome in the pediatric age.Eur. Rev. Med. Pharmacol. Sci.20061025359 16705949
    [Google Scholar]
  10. CrayneC.B. AlbeituniS. NicholsK.E. CronR.Q. The immunology of macrophage activation syndrome.Front. Immunol.20191011910.3389/fimmu.2019.00119 30774631
    [Google Scholar]
  11. SharmaP. ShreshthaS. KumarP. SharmaR. MahapatraT.K. A review on macrophage activation syndrome.J. Pure Appl. Microbiol.201913118319110.22207/JPAM.13.1.19
    [Google Scholar]
  12. SchulertG.S. GromA.A. Pathogenesis of macrophage activation syndrome and potential for cytokine- directed therapies.Annu. Rev. Med.201566114515910.1146/annurev‑med‑061813‑012806 25386930
    [Google Scholar]
  13. RavelliA. DavìS. ParodiA. Macrophage activation syndrome: Practice essentials, pathophysiology, etiology.2024Available from: https://emedicine.medscape.com/article/1380671-overview?form=login
  14. MinoiaF. DavìS. HorneA. Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: A multinational, multicenter study of 362 patients.Arthritis Rheumatol.201466113160316910.1002/art.38802 25077692
    [Google Scholar]
  15. NierengartenM.B. ACR/ARHP annual meeting: Macrophage activation syndrome.2014Available from: https://www.the-rheumatologist.org/article/2014-acrarhp-annual-meeting-macrophage-activation-syndrome/
  16. CascellaM. RajnikM. AleemA. Features, evaluation, and treatment of coronavirus (COVID-19).In: StatPearls.Treasure Island, FLStatPearls Publishing2024
    [Google Scholar]
  17. Al-JamalH. IdrissS. RoufayelR. Abi KhattarZ. FajlounZ. SabatierJ.M. Treating COVID-19 with medicinal plants: Is it even conceivable? A comprehensive review.Viruses202416332010.3390/v16030320 38543686
    [Google Scholar]
  18. Martínez-GarcíaJ.J. López-AcostaJ.R. Arce-CabreraD. Case report: Multisystem inflammatory syndrome in children associated with COVID-19, macrophage activation syndrome, and incomplete Kawasaki disease.Front Pediatr.202311116782810.3389/fped.2023.1167828 37138560
    [Google Scholar]
  19. AbdelgabarA. ElsayedM. A case of delayed COVID-19-related macrophage activation syndrome.J. Med. Cases202213520721110.14740/jmc3903 35655624
    [Google Scholar]
  20. AnnweilerC. CaoZ. WuY. Counter-regulatory ‘renin-angiotensin’ system-based candidate drugs to treat COVID-19 diseases in sars-cov-2-infected patients.Infect. Disord. Drug Targets202020440740810.2174/22123989MTA2cNzIlw 32418532
    [Google Scholar]
  21. El-ArifG. FarhatA. KhazaalS. The renin-angiotensin system: A key role in SARS-COV-2-induced COVID-19.Molecules20212622694510.3390/molecules26226945 34834033
    [Google Scholar]
  22. El-ArifG. KhazaalS. FarhatA. Angiotensin II type I receptor (AT1R): The gate towards COVID-19-associated diseases.Molecules2022277204810.3390/molecules27072048 35408447
    [Google Scholar]
  23. KhazaalS. HarbJ. RimaM. The pathophysiology of long COVID throughout the renin-angiotensin system.Molecules2022279290310.3390/molecules27092903 35566253
    [Google Scholar]
  24. SabatierJ-M. FajlounZ. LegrosC. COVID-19 and ehlers-danlos syndrome: The dangers of the spike protein of SARS-CoV-2.Infect. Disord. Drug Targets2023233e04012321237510.2174/1871526523666230104145108 36600622
    [Google Scholar]
  25. FajlounZ. Abi KhattarZ. KovacicH. LegrosC. SabatierJ.M. Why do athletes develop very severe or fatal forms of covid after intense exercise following SARS-CoV-2 infection or Anti-COVID vaccination?Infect. Disord. Drug Targets2023234e11012321256310.2174/1871526523666230111104355 36631923
    [Google Scholar]
  26. FajlounZ. Abi KhattarZ. KovacicH. LegrosC. SabatierJ.M. SIBO: The trail of a “New” human pathology associated with multiple severe and disabling COVID-19 and long covid symptoms or induced by the anti-COVID-19 vaccine.Infect. Disord. Drug Targets2023234e10022321359310.2174/1871526523666230210162334 36762752
    [Google Scholar]
  27. FajlounZ. Abi KhattarZ. KovacicH. LegrosC. SabatierJ.M. Anti-COVID-19 vaccination, COVID-19, and female contraception: The exacerbated risks (Thromboembolism) of the estrogen-progestin pill.Infect. Disord. Drug Targets2023234e24022321400010.2174/1871526523666230224094439 36823996
    [Google Scholar]
  28. FajlounZ. Abi KhattarZ. KovacicH. LegrosC. SabatierJ.M. Understanding and relieving of neuropathic disorders in the long COVID.Infect. Disord. Drug Targets2023234e27022321406110.2174/1871526523666230227113205 36843369
    [Google Scholar]
  29. FajlounZ. Abi KhattarZ. KovacicH. SabatierJ.M. COVID-19 and anti-COVID-19 vaccination: Potential damages to the thyroid gland.Infect. Disord. Drug Targets2023236e09052321669810.2174/1871526523666230509112038 37165584
    [Google Scholar]
  30. FajlounZ. WuY. CaoZ. KovacicH. SabatierJ.M. COVID-19 and alzheimer’s disease: The link finally established.Infect. Disord. Drug Targets20232371416 37254552
    [Google Scholar]
  31. FajlounZ. WuY. CaoZ. KovacicH. SabatierJ.M. COVID-19 and parkinson’s disease: The link also established!Infect. Disord. Drug Targets2023 37340743
    [Google Scholar]
  32. FajlounZ. KhattarZ.A. SabatierJ.M. The intriguing connection between cholestasis and the renin-angiotensin system dysregulation induced by SARS-CoV-2 and/or the vaccinal spike protein.Infect. Disord. Drug Targets2024247e08032422780210.2174/0118715265304515240220105152 38465438
    [Google Scholar]
  33. TajerL. PaillartJ.C. DibH. SabatierJ.M. FajlounZ. Abi KhattarZ. Molecular mechanisms of bacterial resistance to antimicrobial peptides in the modern era: An updated review.Microorganisms2024127125910.3390/microorganisms12071259
    [Google Scholar]
  34. FajlounZ. Abi KhattarZ. SabatierJ.M. SARS-CoV-2 or vaccinal spike protein can induce mast cell activation syndrome (MCAS).Infect. Disord. Drug Targets20242413 38693735
    [Google Scholar]
  35. FajlounZ. SabatierJ.M. The unsuspected role of the renin-angiotensin system (RAS): Could its dysregulation be at the root of all non-genetic human diseases?Infect. Disord. Drug Targets2024241e14092322108510.2174/1871526524666230914114524 37711109
    [Google Scholar]
/content/journals/iddt/10.2174/0118715265341206240722050403
Loading
/content/journals/iddt/10.2174/0118715265341206240722050403
Loading

Data & Media loading...


  • Article Type:
    Editorial
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test